Inhibikase Therapeutics
IKT
IKT
24 hedge funds and large institutions have $6.33M invested in Inhibikase Therapeutics in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Holders
24
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$245K | |
| 2 | +$182K | |
| 3 | +$76.1K | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$19K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$7.48K |
Top Sellers
| 1 | -$484K | |
| 2 | -$327K | |
| 3 | -$200K | |
| 4 |
RPCONE
Retirement Planning Company of New England
Warwick,
Rhode Island
|
-$45.7K |
| 5 |
Renaissance Technologies
New York
|
-$18.8K |